ANIK Financial Facts

Total operating expenses: 11.77M
Licensing, milestone and contract revenue: 80.11K
See Full Income Statement

Cash and cash equivalents: 71.77M
Total current assets: 128.66M
See Full Balance Sheet

Anika Therapeutics Inc. (ANIK) Earnings

  |   Expand Research on ANIK
Next EPS Date 2/26/15 *Est. EPS Growth Rate +21.2% *Last Qtr.
Average EPS % Beat Rate +79.8% Revenue Growth Rate +24.2% *Last Qtr.
Average % Move 1-Wk after EPS -4.1% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/4/11 Q111 $0.02N/A N/A $11.7MN/A N/A Details
3/9/11 Q410 $0.10N/A N/A $14.2MN/A N/A Details
8/4/11 Q211 $0.17N/A N/A $16.1M$13.7M N/A Details
2/29/12 Q411 $0.21N/A N/A $18.4M$14.7M N/A Details
11/2/11 Q311 $0.22$0.11 +$0.11$18.5M$15.1M N/A Details
10/30/13 Q313 $0.33$0.14 +$0.19$17.8M$16.96M N/A Details
10/30/12 Q312 $0.11$0.17 -$0.06$14.8M$16.83M N/A Details
5/3/12 Q112 $0.14$0.17 -$0.03$14.4M$18.2M N/A Details